Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
Annual shareholder meeting highlights
-
LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
MINNEAPOLIS, MN, Jan. 21, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., in cooperation with its parent PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and affiliate PetVivo AI, Inc., an...
-
Nutriband New Year Letter to Shareholders
-
Quanta LOI
-
Fentanyl designation Response
-
Revolutionary Veterinary AI Platform Ditches Dense Documentation in Favor of Clear, Engaging Video Walkthrough MINNEAPOLIS, MN, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo.ai, the AI powered platform...
-
Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that...